Barclays PLC Centessa Pharmaceuticals PLC Transaction History
Barclays PLC
- $377 Billion
- Q3 2024
A detailed history of Barclays PLC transactions in Centessa Pharmaceuticals PLC stock. As of the latest transaction made, Barclays PLC holds 350 shares of CNTA stock, worth $5,761. This represents 0.0% of its overall portfolio holdings.
Number of Shares
350
Previous 350
-0.0%
Holding current value
$5,761
Previous $6,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding CNTA
# of Institutions
107Shares Held
118MCall Options Held
5.9KPut Options Held
53K-
Medicxi Ventures Management (Jersey) LTD20MShares$329 Million73.44% of portfolio
-
Index Venture Life Associates Vi LTD St. Helier, Y99.96MShares$164 Million100.0% of portfolio
-
General Atlantic LLC New York, NY9.68MShares$159 Million4.42% of portfolio
-
Perceptive Advisors LLC New York, NY6.28MShares$103 Million2.62% of portfolio
-
First Light Asset Management, LLC Edina, MN5.94MShares$97.8 Million8.27% of portfolio
About Centessa Pharmaceuticals plc
- Ticker CNTA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,339,296
- Market Cap $1.55B
- Description
- Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; an...